Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2)

Benzer Materyaller

• Protein phosphatase PP5 controls bone mass and the negative effects of rosiglitazone on bone through reciprocal regulation of PPARγ (peroxisome proliferator-activated receptor γ) and RUNX2 (runt-related transcription factor 2).
  Yazar:: Stechschulte, Lance A., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Reciprocal regulation of PPARγ and RUNX2 activities in marrow mesenchymal stem cells: Fine balance between p38 MAPK and Protein Phosphatase 5
  Yazar:: Stechschulte, Lance A., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass.
  Yazar:: Vipula Kolli, ve diğerleri
  Baskı/Yayın Bilgisi: (2014-01-01)
• Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass
  Yazar:: Kolli, Vipula, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARγ Agonist Rosiglitazone
  Yazar:: Stechschulte, Lance A., ve diğerleri
  Baskı/Yayın Bilgisi: (2016)